The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...
Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.
Amerigo Scientific launched a comprehensive portfolio of GMP-grade proteins tailored to accelerate the development and ...
The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...
Cellares has raised a $257 million Series D financing, bringing its total funding to $612 million. The latest comes as the cell therapy manufacturing company accelerates plans to industrialize ...
Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...
Pluri (PLUR), an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) ...
USANewsGroup.com News Commentary -- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical breakthroughs and manufacturing milestones reshaping ...
Healthcare Asia Magazine on MSN
Gene and cell therapy boom drives DNA manufacturing market toward $21.82B by 2034
Biotech investments fuel DNA manufacturing in Asia-Pacific. The global DNA manufacturing market is projected to reach $21.82b ...
Pharmaceutical manufacturer Johnson & Johnson is expanding its operations in Pennsylvania by building a new cell therapy manufacturing facility in Lower Gwynedd Township.
Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after inking a long-term lease for manufacturing and office space in the Netherlands.
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results